Excellent point. I didn't think of that. If pona is proves effective at lower doses (or no AEs with screening, or initial dose of 45 with drop to 30 or less shortly thereafter), the case for first line use could actually be quite plausible.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.